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ExperWHAT THIS PAPER ADDS
This experimental study on pigs shows that both ex vivo and in vivo, locally administered dual antiplatelet and
anticoagulant (APAC) targets the vascular injury sites under normal and high flow conditions in an acute setting.
In the vein and in the balloon injured artery, APAC also penetrates the vessel wall. The binding counterparts
include internal elastic lamina, von Willebrand factor, and laminin. These characteristics render APAC a prom-
ising novel substance/therapy for both endovascular and open vascular surgery to resist excessive local platelet
aggregation and acute clotting at the site of endothelial injury.Objectives: Vascular binding of dual antiplatelet and anticoagulant (APAC) was assessed in surgically created
femoral arteriovenous fistula (AVF) and iliac and carotid artery injury in porcine models.
Methods: Three models of collagen exposing injury were used: 1) femoral AVF, 2) in vivo iliac and carotid artery
balloon angioplasty injury, and 3) in vitro femoral artery endothelial denudation injury. Biotinylated APAC
(0.5 mg/mL) was incubated with the injury site before releasing blood flow. APAC, von Willebrand factor
(vWF), laminin, platelet endothelial cell adhesion molecule 1 (PECAM-1), and podocalyxin were detected in
histological sections using immunofluorescence and confocal microscopy and Manders’ co-localisation
coefficient (M1).
Results: APAC bound to AVF at anastomosis and to both in vivo and in vitro injured arteries. APAC co-localised
with matrix vWF (M1  0.66) and laminin (M1  0.60), but less so if endothelial PECAM-1 or podocalyxin was
present (M1  0.25). APAC targeted and penetrated the injured vessel wall, especially the AVF vein.
Conclusions: APAC, compatible with its high negative charge, rapidly targets injured vessels co-localizing with
matrix vWF and laminin, but not with endothelial PECAM-1 and podocalyxin. This localising feature may have
potential antithrombotic implications for vascular interventions.Keywords: APAC, Arteriovenous fistula, Balloon angioplasty, Porcine vascular injury model, Von Willebrand factor
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imental Porcine Model, European Journal of Vascular and Endovascular SurgIn vascular procedures, local iatrogenic vascular injury at
the site of an intervention is unavoidable and interaction
with blood and its constituents will follow to initiate heal-
ing. The extension of blood coagulation is prohibited by
systemic anticoagulation with a weight adjusted intrave-
nous infusion of unfractionated heparin (UFH) and platelet
inhibitors.4
Often, vascular patients receive pre-operative oral anti-
platelet therapy (i.e. aspirin or clopidogrel) as secondary
prevention.5,6 Currently, as locally administrable antiplatelet
regimens are not available for clinical use, systemic expo-
sure to antiplatelet agents together with heparins or other
anticoagulants increases peri- and post-operative challenges
to haemostasis.7e9let and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an
ery, https://doi.org/10.1016/j.ejvs.2019.05.019
2 Karina A. Barreiro et al.Semisynthetic antiplatelet and anticoagulant (APAC),
with its dual action, is a heparin proteoglycan (HEP-PG)
mimic designed for vascular interventions.7,8,10 APAC com-
prises UFH chains conjugated to a protein core, rendering
APAC a unique, locally acting antithrombotic. APAC specif-
ically inhibits collagen induced platelet aggregation and
subsequent thrombus growth, but maintains haemostasis,
the key initiator of healing after vascular injury. APAC in-
hibits mainly the intrinsic pathway of coagulation and in-
duction of thrombin generation on platelet surfaces,
reducing fibrin formation at the site of arterial injury, thus
acting as an anticoagulant.10 The pharmacokinetics of sys-
temically administrated APAC have been defined in rats,11
and the benefits of locally administered APAC are
described in two short term (one to two hours) baboon
arterial injury models and in long term (two weeks) healing
of rat arterial anastomosis.10 Interestingly, intravenously
administered APAC also shows significant vasculoprotective
effects by preventing ischaemic kidney injury.10,11
The injury associated antithrombotic effects allows this
therapeutic agent to control collagen and thrombin medi-
ated platelet aggregation and thrombus formation at the
site of a vascular intervention. Although APAC has shown its
antithrombotic potential in earlier studies, the vascular
interaction and binding sites are unknown. Several models
of small and large animals have been developed for vascular
injury research, but porcine vascular injury carries histo-
logical changes best reflecting those described in
humans.12,13 Thus, in the present study, the porcine model
was chosen to investigate early binding and co-localisation
of locally administered APAC at the site of an experi-
mental human like balloon angioplasty and arteriovenous
fistula (AVF) before entering human studies.14METHODS
For a detailed description of materials and methods, see the
Supplementary Material. In brief, in vivo two injury models
were used: 1. the creation of an AVF between the femoral
artery (FA) and vein (FV) to mimic open vascular surgery
under high blood flow conditions, and 2. balloon injury of
iliac (IA) and carotid arteries (CA) to mimic endovascular
surgery/procedures. In vitro in the absence of blood, the
arterial injury site was incubated with APAC to assess direct
vascular binding. All animal procedures were performed on
female landrace pigs (n ¼ 5, mean weight 30 kg) under
general anaesthesia with the approval (ESAVI-7811-
4.10.2016) of the Regional State Administrative Agency for
Southern Finland and in accordance with the guidance and
legislation for animal experimentation. An overview of the
experiments performed is presented in Table S1.
Blood cell counts and activated partial thromboplastin
time (APTT) were analysed for all animals. Animals received
peri-operative UFH and one animal was pre-dosed with
100 mg of aspirin to test the haemostatic effect of its co-
administration in the model. An AVF was created bilaterally
end to side between the FA and FV, and the anastomotic area
was incubated with either phosphate buffered saline (PBS) orPlease cite this article as: Barreiro KA et al., Novel Locally Acting Dual Antiplate
Experimental Porcine Model, European Journal of Vascular and Endovascular SurgAPAC-biotin conjugate (0.25e0.3 mg in 0.5e0.6 mL of PBS)
(henceforth APAC) (Aplagon Ltd., Helsinki, Finland, www.
aplagon.com). Thirty minutes after restoring the circulation,
the anastomosis area was resected, flushed with saline, and
fixed in 10% formalin for histology. Also, a segment of the FA
was collected, mechanically de-endothelialised, and incu-
bated in PBS or APAC in vitro for two minutes, post-fixed in
10% formalin for six hours, snap frozen in liquid nitrogen, and
stored at 80 C.
For endothelial denudation, a percutaneous transluminal
angioplasty (PTA) balloon (Abbott Armada 35, 6  40 mm;
50% oversized) was advanced to the mid portion of the
common IA or CA, inflated to 6 Atm and moved and rotated
10 times back and forth. Next, 3 mL of PBS (always first) or
of APAC (1.5 mg) was slowly released to the denuded area
within two minutes, through a maximally filled OTW
ClearWay diffusion balloon catheter (6  40 mm for IA and
2  20 mm for CA; Atrium Europe B.V., SL Mijdrecht, The
Netherlands). After 30 min of circulation, the arterial
segment was resected and post-fixed as AVF (Fig. S1).
For histology, 10 mm cryo-sections and haematoxylin
eosin staining were used. For immunofluorescent staining,
APAC was detected with streptavidin-eFluor 660 (50-4317,
eBioscience Inc., Affymetrix Inc., San Diego, CA, USA) or
streptavidin-ATTO647 (Immune Biosolutions, Sherbrooke,
QC, Canada), and antibodies for von Willebrand factor
(vWF), laminin, platelet endothelial cell adhesion molecule
1 (PECAM-1), or podocalyxin were used and detected with
corresponding secondary antibodies.
Samples were analysed with confocal microscopes of
Leica (TCS CARS SP8) or Zeiss (LSM 780). Co-localisation for
directly bound APAC and vWF, laminin, or PECAM-1, was
analysed with the plug in coloc2 for imageJ (NIH, USA) and
Mander’s method to estimate co-localisation.15 Maximum
projection images and enhanced contrast (linear adjust-
ment, ImageJ) were used for figure panels.Statistics
Blood cell counts are expressed as change (%) relative to
the baseline value, and APTT as mean(s)  standard devi-
ation (SD). The reported Manders’ co-localisation co-
efficients M1 (M1) were background corrected and
expressed as mean  standard error of the mean (SEM). A
one tailed paired samples t test was conducted to compare
M1 for APAC-vWF with APAC-PECAM-1, in both AVF and
balloon injuries, and differences were analysed with IBM
SPSS statistics V24. A p value of  0.05 was considered
statistically significant.RESULTS
Blood cell counts and coagulation
At baseline, the range of blood cell counts was normal, but
they decreased at the end of the four to five hour experi-
ments, mostly platelet counts, by 35% (Table S2), reflecting
their consumption during the study.let and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an
ery, https://doi.org/10.1016/j.ejvs.2019.05.019
Locally Acting APAC Targets Vascular Injury Site 3APTT was used to assess the systemic effects of IV UFH
bolus, excluding those of local APAC administration. Baseline
APTT was 15.6  3.2 s (mean  SD; n ¼ 5), and 10 min after
UFH, APTT was prolonged on average by 1.7  0.6-fold
(26.4  10.3 s; one to three boluses per animal; n ¼ 12) vs.
the baseline. APTT reverted to baseline values 90 min after
each UFH bolus administration. Excluding any systemic effect,
the local APAC did not influence APTT (up to 0.3 mg in AVF,
APTT 14.9  2.9 s; n ¼ 5; or 1.5 mg in balloon injury, APTT
14.7  0.9 s; n ¼ 3). The co-administration of aspirin with
APAC did not influence APTTor haemostasis (data not shown).APAC targets and binds to AVF walls
Under this very high flow (290e590 mL/min) AVF model,
APAC covered broad areas, including the artery, the vein,
and the suture lines (Fig. 1). In the artery, APAC tightly
followed the luminal side, reaching the internal elastic
lamina. In the vein, APAC covered the luminal side, but also
clearly penetrated the deeper layers of the tunica media.APAC targets and binds to balloon injured artery walls
In the in vivo balloon injury models, APAC decorated the
luminal side in close contact with the internal elastic lamina,
compatible with the binding in vitro (Supplementary
Figs. S2AeF, and S3A-C). In the control (PBS) artery, the
signal was negative (Figs. S2GeI). In CAs, the lesion produced
by balloon injury seemed larger than in IAs, and the APAC












Figure 1. Dual antiplatelet and anticoagulant (APAC) distribution
incubated with APAC before opening the circulation. Haematoxyl
between the femoral artery (FA) and femoral vein (FV, A) and the
walls of vein (B-D), suture site (E-G) and artery (H-J). APAC (red
media of vein (C-D), and around the suture sites (F-G). APAC wa
internal elastic lamina (arrow heads). Nuclei (blue; B; D-E; G-H;
lumen. Scale bar corresponds to 20 mm.
Please cite this article as: Barreiro KA et al., Novel Locally Acting Dual Antiplate
Experimental Porcine Model, European Journal of Vascular and Endovascular SurgDirect binding of APAC to in vitro denuded artery
In the in vitro model of denuded FA, illustrating the direct
interaction of APAC without contact with blood flow, the
APAC signal was detected on the luminal side, next to and
following the contour of the internal elastic lamina
(Fig. S3AeC). In the control (PBS) artery, the signal was
absent (Fig. S3DeF). vWF was absent or barely detectable in
in vitro denuded arteries (data not shown).
APAC co-localised with vWF in both AVF and balloon injury
models
To assess APAC’s in vivo molecular interactions, the focus
was on vWF. On the arterial side of the AVF, 66% of the
APAC signal co-localised with vWF (M1 ¼ 0.66  0.03;
n ¼ 3) (Fig. 2). The absence of any luminal nuclei in the
internal elastic lamina (Fig. 2AeD), reflected a lack of
endothelium at the binding sites. In the in vivo balloon
angioplasty, the APAC signal again co-localised with vWF in
70% of the acquisitions (M1 ¼ 0.70  0.05; n ¼ 3) (Fig. 2) in
CAs, confirming the strong interaction. On the venous side,
a similar co-occurrence was noted (Fig. S4), in addition to
the deeper penetration of APAC in the vascular wall.
APAC co-localised with laminin in both AVF and balloon
injury models
To study the targetingofAPAC in subendothelial structures, the
co-localisation between APAC and laminin, the major compo-
nent of the basementmembrane,was assessed.On the arterial




in femoral arteriovenous fistula (AVF) wall in pig. AVF was
in eosin staining at the end-to-side anastomosis site (arrows)
corresponding fluorescent stains of luminal parts of vascular
; C-D; F-G; I-J) was detected at the luminal side and in tunica
s detected at the luminal side of the artery (I-J) outside the
J) were detected with Hoechst stain against DNA. Asterisk ¼
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Figure 2. von Willebrand factor (vWF) and dual antiplatelet and anticoagulant (APAC) double staining of the
luminal sides on the arterial side of femoral arteriovenous fistula (AVF, A) and balloon injured carotid artery walls
(B) in pig. APAC or phosphate buffered saline (PBS) as control was incubated in AVF before opening the circu-
lation and administrated through diffusion balloon catheter in carotid artery. Histological samples were immu-
nostained for vWF (green; ced; geh; kel; oep) and APAC (red; b; d; f; h; j; l; n; p). Hoechst stain (blue) detected
nuclei (a; dee; hei; lem; p). In AVF and balloon injured carotid artery, APAC co-localised with vWF (d; l). In PBS
controls, APAC signal was absent (f; h; n; p). Arrow heads ¼ internal elastic lamina; Asterisk ¼ lumen; Scale bar
corresponds to 20 mm.
4 Karina A. Barreiro et al.60% of the APAC signal co-localised with laminin
(M1 ¼ 0.60  0.08; n ¼ 3, and 0.64  0.05, n ¼ 3) (Fig. 3),
showing APAC along the subendothelial basementmembrane.Limited APAC co-localisation with PECAM-1 and
podocalyxin
To assess the binding of APAC to some patchy areas of intact
endothelial cells, its co-localisationwas studiedwith PECAM-1
and podocalyxin, both expressed by endothelial cells and
platelets. Some luminal areas of intact endothelium were
defined as linearly organised nucleated cells, being positive for
PECAM-1 and/or podocalyxin. On the arterial side of the AVF,Please cite this article as: Barreiro KA et al., Novel Locally Acting Dual Antiplate
Experimental Porcine Model, European Journal of Vascular and Endovascular Surgonly 25% of the APAC signal co-localised with PECAM-1
(M1 ¼ 0.25  0.03; n ¼ 3) (Fig. 4), when present. On the
venous side, PECAM-1 was nearly absent, while strong
penetration of APAC in the venouswall was observed (Fig. S5).
Similarly, in the balloon angioplasty model in CAs, less than
25% of the APAC signal co-localised with PECAM-1
(M1 ¼ 0.22  0.04; n ¼ 3) (Fig. 4). These values indicate
that less than 25% of any of the signals co-localised with
another signal. The M1 of APAC-vWF and APAC-PECAM-1
differed significantly in both AVF and balloon injury
(t(2) ¼ 8.2, p < .01 and 61.8, p < .001, respectively). In
agreementwith the results of PECAM-1, the presence of APAC
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Figure 3. Laminin and dual antiplatelet and anticoagulant (APAC) double staining in arterial side of femoral
arteriovenous fistula (AVF, A) and balloon denuded carotid artery (B) in pig. APAC or phosphate buffered saline
(PBS) as control was incubated in AVF before opening the circulation and administrated through diffusion balloon
catheter in carotid artery. Histological samples were stained for laminin (a1/b1/Ƴ1 chains, green; ced; geh; kel;
oep) and APAC (red, b, d, f, h, j, l, n, p). Hoechst stain (blue) detected nuclei (a, dee, hei, lem, p). APAC co-
localised with laminin (d; l). In PBS controls, APAC signal was absent (f; h; n; p). Arrow heads ¼ internal
elastic lamina; Asterisk ¼ lumen. Scale bar corresponds to 20 mm.
Locally Acting APAC Targets Vascular Injury Site 5PECAM-1 and podocalyxin are both also expressed by plate-
lets, but staining occurred in nucleated cells, and the antibody
did not detect any signal in the white thrombi present locally
in some areas of the AVFs.16,17DISCUSSION
APAC, a mast cell derived HEP-PG mimic, is a semisynthetic
conjugate of multiple heparin chains, which unlike UFH or
any other current antithrombotic, has dual antiplatelet and
anticoagulant properties. These have been characterised via
several methods both in vitro and in vivo, leading to the
name APAC (AntiPlatelet-AntiCoagulant).7,8,10 Locally
administered HEP-PG or APAC inhibits thrombus formationPlease cite this article as: Barreiro KA et al., Novel Locally Acting Dual Antiplate
Experimental Porcine Model, European Journal of Vascular and Endovascular Surgat the vascular injury site or collagen surface and by binding
remains at the site of vascular injury.8,10,17 To better delin-
eate these specific vascular targeted interactions, the histo-
logical localisation of biotinylated APAC was studied at the
injured vascular wall using various injury models, including
the clinically relevant in vivo surgically created femoral AVF,
IA and CA balloon injury, and in vitro mechanically denuded
(scraped) FA. APAC multivalently targeted vascular injury
sites by co-localizing with subendothelial structures, specif-
ically with vWF and laminin. In contrast, APAC did not bind
to vascular areas in which the endothelium seemed intact.
The binding of APAC persisted at the site of injury even
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Figure 4. Platelet endothelial cell adhesion molecule 1 (PECAM-1) and dual antiplatelet and anticoagulant
(APAC) double staining of femoral arteriovenous fistula (AVF) (A) and balloon injured carotid artery (B) in pig.
APAC or phosphate buffered saline (PBS) as control was incubated in AVF before opening the circulation and
administrated through diffusion balloon catheter in carotid artery. Histological samples were stained for platelet
endothelial cell adhesion molecule 1 (PECAM-1; green; c-d; g-h; k-l; o-p) and for APAC (red, b, d, f, h, j, l, n, p).
Hoechst stain (blue) detected nuclei (a, d-e, h-i, l-m, p). APAC did not co-localise with PECAM (d; l). In PBS
controls, APAC signal was absent (f-h; n-p). Arrow heads ¼ internal elastic lamina; Asterisk ¼ lumen. Scale bar
corresponds to 20 mm.
6 Karina A. Barreiro et al.endovascularly administrated via the specific porous angio-
plasty balloon. As antiplatelet and anticoagulation effects are
beneficial during endovascular interventions,5,6 APAC could
provide a sound option for preventing thrombotic compli-
cations at application sites.10,11,18APAC directly interacts with the site of vascular injury in
vitro in the absence of blood flow
During vascular injury the subendothelial basement mem-
brane and the deeper layers of the vascular wall, rich in
collagen, make contact with blood and initiate haemostasis,
which may proceed to thrombosis. This results from thePlease cite this article as: Barreiro KA et al., Novel Locally Acting Dual Antiplate
Experimental Porcine Model, European Journal of Vascular and Endovascular Surgactivation of coagulation and platelets via their glycoprotein
receptors, which interact with vWF and collagen in the
flowing blood, especially under high shear forces.3
In the in vitro model of mechanically denuded FA,
without blood contact and endothelium, APAC provided the
signal directly at the subendothelial areas in the absence of
vWF. The present results show that direct binding of the
highly negatively charged APAC to the positively charged
extracellular matrix can also occur in the absence of blood
or plasma components, and specifically, also in the absence
of vWF in situ.16let and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an
ery, https://doi.org/10.1016/j.ejvs.2019.05.019
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Figure 5. Podocalyxin and dual antiplatelet and anticoagulant (APAC) in femoral arteriovenous fistula (AVF). in
pig. APAC or phosphate buffered saline (PBS) as control was incubated in AVF before opening the circulation and
administrated through diffusion balloon catheter in carotid artery. Histological samples were stained for podo-
calyxin (green; C-D; G-H) and APAC (red; B; D; F; H). Hoechst stain (blue) detected nuclei (A; D-E; H). APAC signal
was reduced in the podocalyxin positive areas (D). In PBS controls, APAC signal was absent (H). Arrow heads ¼
internal elastic lamina; Asterisk ¼ lumen. Scale bar corresponds to 20 mm.
Locally Acting APAC Targets Vascular Injury Site 7APAC interacts in vivo with the site of vascular injury in the
presence of blood flow
To study the influence of blood and its flow conditions on the
interactive mechanisms of APAC and the vascular wall during
vascular injury, two in vivo porcinemodels of severe IA and CA
balloon injury were used. APAC was able to target and persist
in the vascular wall after being subjected to the flushing effect
of restored circulation, even resisting the AVF high flow con-
ditions, indicating strong binding. APAC was administered
locally to the vascular site using a porous angioplasty balloon.
These techniques provide a practical rationale for APAC
application and may also suggest other administration
methods, that is covered stents or drug eluting balloons.APAC binds in vivo to balloon injury sites with absent
endothelium co-localizing with vWF and laminin
In the present balloon injury model, APAC mostly decorated
the luminal surface without endothelium. The overlapping of
APAC with vWF and laminin was 60e70% (M1). In addition
to laminin, subendothelium contains collagens, that is
collagen IV in the basal lamina, binding negatively charged
heparins.19 APAC overall interacts with the positively
charged extracellular matrix components and plasma factors.
At the balloon injury site, APAC infiltrated to the tunica
media, but did not follow the elastic lamina, suggesting
APAC’s preference for extracellular matrix. Mast cell derived
macromolecular HEP-PG, the model for APAC, attenuated
platelet-collagen interactions in both soluble and immobi-
lised form on collagen, and under high blood flow, the effect
mediated by vWF.7,8 Similar results were obtained recently
on the role of vWF inhibition by APAC under blood perfusionPlease cite this article as: Barreiro KA et al., Novel Locally Acting Dual Antiplate
Experimental Porcine Model, European Journal of Vascular and Endovascular Surgover collagen and tissue factor, where APAC reduced platelet
deposition at the arterial shear rate.20
APAC is retained in AVF and vascular injury under high
flow conditions
High shear stress blood flow causes endothelial cell acti-
vation and enhances platelet adhesion through vWF, lead-
ing to thrombus formation.21 In an earlier study on
collagenous AVF loop grafts, APAC reduced platelet depo-
sition, distal thrombus propagation, and fibrin accumula-
tion, unlike UFH.10 In this study, there was APAC binding to
the AVF on the artery and vein luminal surfaces lacking
endothelium, and APAC penetrated the vein. The stable co-
localisation of APAC with vWF and laminin was similar in
balloon injuries, suggesting that the interaction between
APAC under high arterial flow conditions and vWF origi-
nates from sources other than endothelium, that is platelets
and plasma. The outcome of vascular interventions, that is
the AVF, is impaired by thrombophilic traits, and there is an
urgent need for novel antithrombotic strategies to maintain
AVF patency.22
APAC lacks systemic effects when administrated locally
UFH is used widely during vascular surgery, as systemic
anticoagulation is needed when manipulating vessels,5,6 but
the patients are simultaneously at risk of bleeding. APAC
attenuated haemostasis in the rat tail bleeding model at
high systemic (IV) doses, but less than UFH at compatible
APTT levels.10 As in previous in vivo baboon studies of local
small dose (2 mg) APAC,10 no increase in systemic anti-
coagulation was detected in pigs, suggesting safety of APAC
integration. As the majority of vascular patients will be onlet and Anticoagulant (APAC) Targets Multiple Sites of Vascular Injury in an
ery, https://doi.org/10.1016/j.ejvs.2019.05.019
8 Karina A. Barreiro et al.aspirin or other platelet inhibitors peri-operatively co-
administered with UFH, safety is paramount.Study limitations
The follow up time of APAC interaction was short, only
30 min, and long term effects cannot be predicted. How-
ever, the current study was designed as the first step in the
investigation of the early vascular vessel wall interaction
with APAC. It aimed at piloting APAC’s initial binding
counterparts in the vascular wall at clinically relevant sites
in vascular surgical approaches. The focus was on immedi-
ate APAC targeting on vascular structures, but there was no
follow up on thrombus formation. In any case, it is shown
that a short incubation time leads to firm binding of APAC
during the period following open circulation, even under
the high flow conditions of an AVF, providing a foundation
for further studies. As the previous data in rats showed PET
labelled APAC retention for at least 50 h at the application
site,10 a longer impact can be assumed also in these current
models. Although the present histological data demonstrate
the co-localisation of APAC with collagens, vWF, or laminin,
the time course and longer follow up are warranted in these
models. Also, because of species specific differences, the
present results should be extrapolated with caution.CONCLUSIONS
This study shows that APAC is easy to administer to target
vascular injury and persists at the site under both normal
and high arterial blood flow. APAC binding preferred vWF,
laminin, and the basal lamina collagen, but vascular inter-
action of APAC was observed also in the absence of vWF.
APAC did not target preserved endothelial areas. This
localising feature may have potential antithrombotic impli-
cations for vascular interventions.CONFLICT OF INTEREST
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